Second Xiangya Hospital, Zhihuiyan Partner for AI-Driven Precision Medicine

On April 12, the Second Xiangya Hospital of Central South University and Zhihuiyan Technology Co., Ltd. (hereinafter referred to as "Zhihuiyan") signed a strategic cooperation agreement. This partnership aims to integrate AI technology with medical practices to enhance precision medicine, improve diagnostic accuracy, and optimize treatment plans. The collaboration will focus on medical and engineering integration, industrial and medical integration, scientific research, talent cultivation, and achievement transformation.

The hospital's director, Lü Běn, highlighted that this collaboration is a significant step in the cross-disciplinary integration of medicine and technology. He expressed hope that it would provide more efficient and convenient medical services to patients. Zhihuiyan's chairman, Qiu Jianhua, emphasized that the Second Xiangya Hospital is a leading institution in China's medical field, with comprehensive strengths ranking among the top in the country. He noted that this strategic cooperation is a crucial step for Zhihuiyan in deepening its involvement in the medical AI ecosystem. The company aims to drive the integration of AI with medical scenarios through technological innovation, empowering the hospital's high-quality development and contributing to the construction of a healthy China.

The Second Xiangya Hospital is a renowned tertiary general hospital known for its excellence in psychiatry and metabolic endocrinology, among other specialties. By leveraging Zhihuiyan's expertise in AI, large model technology, and medical digitalization, the two entities will jointly develop AI medical solutions covering medical services, patient services, and clinical research. These solutions aim to enhance disease diagnosis and treatment efficiency, optimize patient medical experiences, and strengthen the hospital's fine management capabilities, ultimately driving the improvement and efficiency of medical services.

In the field of chronic kidney disease, where some patients may progress to end-stage renal disease (uremia), Zhihuiyan has accumulated a full-chain technology in the management of chronic kidney disease and urology. Through this collaboration, the two parties will leverage the advantages of the CanShi large model technology to establish specialized large models. The focus will be on two innovative directions: in the field of chronic kidney disease (CKD), using intelligent algorithms to build a visual diagnostic platform that enables intelligent prediction and precise intervention of disease progression; and in the field of renal tumors and male reproductive health, using big data analysis technology to develop prognosis evaluation and rehabilitation prediction systems, establishing an intelligent decision support system.

By leveraging their respective strengths in academic resources, research capabilities, and technological reserves, the two parties will build digital doctor avatars and patient health portraits. This will enhance the rescue capabilities for major diseases and provide replicable models for the innovative development of precision medicine. As AI and medical integration deepen, the smart healthcare sector is entering a critical development phase. Zhihuiyan plans to collaborate with more medical institutions in the future to build a smart health ecosystem and promote the implementation of universal healthcare.